Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

Richard E. Pratley MD Associate Editor

Deborah J. Wexler MD, MSc Associate Editor

Kathleen M. Dungan MD, MPH Advisory Board

See All Experts

featured

Published in Diabetes

Journal Scan / Research · October 11, 2023

Teplizumab: A Disease-Modifying Agent for Type 1 Diabetes That Preserves β-Cell Function

Diabetes Care

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Article Citation

Diabetes Care

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function

Diabetes Care 2023 Oct 01;46(10)1848-1856, KC Herold, SE Gitelman, PA Gottlieb, LA Knecht, R Raymond, EL Ramos

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Teplizumab: A Disease-Modifying Agent for Type 1 Diabetes That Preserves β-Cell Function

Additional Info

Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function

Further Reading

Final Note From the Diabetes Editors

Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes — 2025

Efficiency of CGM in Predicting Gestational Diabetes and Perinatal Complications

Effect of Sarcopenic Obesity on the Progression of Glycaemic Status in Middle-Aged and Older Adults Without Diabetes

Use of SGLT2 Inhibitors Reduces Epicardial Adipose Tissue More Effectively Compared With GLP-1 Agonists or Exercise in Patients With Type 2 Diabetes and/or Obesity

Prevalence of Metabolic Syndrome Among Children and Adolescents With Obesity

Improving Care and Promoting Health in Populations: Standards of Care in Diabetes — 2025

Perinatal Outcomes in Patients With Early vs Late Gestational Diabetes Mellitus Treated Between 24 and 28 Weeks of Gestation

Association Between Bone Mineral Density and the Risk of Kidney Disease Progression in Patients With Type 1 Diabetes

Role of Intermittent Fasting in Weight Management and Improving Metabolic Health

Consensus Considerations and Good Practice Points for the Use of CGM Systems in Hospital Settings

Recently Updated